mGx M&A? Moderna execs are leveraging their Covid cash on gene editing, gene therapy deals
Moderna’s little business deal with Autolus earlier this week looks like a predinner snack ahead of the main course to come.
During his Q2 call with analysts on Thursday, Moderna CEO Stéphane Bancel got more than a few eyebrows to raise with his comments on BD plans. Now that the company’s market cap has hit an Everest-high cruising altitude above $165 billion — levitating up 78% in the past month — with a megablockbuster ginning money on hand, Bancel is prepared to put that cash and kind to use. And he made it clear that gene editing/gene therapies are right at the heart of this new move.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.